Sens. Rand Paul (R-KY) and Cory Booker (D-NJ) (Olivier Douliery/Sipa USA/Sipa via AP Images)

November 18, 2022 03:06 PM ESTUpdated November 22, 11:27 AM

Congress takes another look at reclassifying psilocybin and MDMA

Nicole DeFeudis

Editor

Months after Sens. Cory Booker (D-NJ) and Rand Paul (R-KY) introduced a bill that would expand access to Schedule I drugs for terminally ill patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Congress takes another look at reclassifying psilocybin and MDMA

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Con­gress takes an­oth­er look at re­clas­si­fy­ing psilo­cy­bin and MD­MA

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Congress takes another look at reclassifying psilocybin and MDMA